Sangamo Therapeutics, Inc. (SGMO) Latest Stock News
Get the latest Sangamo Therapeutics, Inc. (SGMO) stock news and headlines to help you in your trading and investing decisions.
News Releases | Investor Relations - Sangamo Therapeutics, Inc.
Nov 4, 2024 · Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to $1.9 billion in milestone.
Sangamo Therapeutics Stock Plunges As Pfizer Terminates …
6 days ago · On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for ...
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia …
6 days ago · Sangamo Therapeutics (SGMO) shares cratered more than 50% Tuesday, a day after the biopharma firm announced that Pfizer (PFE) had pulled out of its deal to co-develop a hemophilia drug.
Sangamo To Regain Rights To Hemophilia Therapy After Pfizer's …
Dec 30, 2024 · (RTTNews) - Genomic medicine company Sangamo Therapeutics, Inc. (SGMO) Monday announced that it will regain development and commercialization rights to giroctocogene fitelparvovec that it has co ...
Sangamo (SGMO) Stock Plunges After Pfizer Ends Pact for …
Dec 30, 2024 · Sangamo Therapeutics Inc. shares fell the most in 16 years after Pfizer Inc. ended the two companies’ partnership to develop a new gene therapy to treat hemophilia A.
Sangamo Therapeutics, Inc. (SGMO) Latest Stock News
Get the latest Sangamo Therapeutics, Inc. (SGMO) stock news and headlines to help you in your trading and investing decisions.
Sangamo Therapeutics Plunges 60% As Pfizer Terminates ... - Nasdaq
Dec 31, 2024 · SGMO has traded in a range of $0.30 to $3.18 in the last 1 year. The stock closed Monday's trading at $2.34, down 8.59%. In after-hours, the stock plunged 60.38% to $0.92.
Sangamo stock rallies 37% on FDA update for Fabry disease drug
Sangamo Therapeutics (NASDAQ: SGMO) shares rallied 37% in early trading Tuesday on news the company can file for FDA accelerated approval of its drug ST-920 for the treatment of Fabry disease...
Why Sangamo stock plunged on Pfizer deal exit (SGMO:NASDAQ)
6 days ago · Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the reasons for the selloff.
- Some results have been removed